Recognizing Serious Side Effects of Keytruda
Keytruda (pembrolizumab) is an immunotherapy that boosts the immune system to fight cancer but can trigger immune-related adverse events (irAEs), where the immune response attacks healthy tissues. Serious side effects include severe inflammation in organs like lungs (pneumonitis), colon (colitis), liver (hepatitis), endocrine glands (hypophysitis or thyroiditis), skin (severe rash), kidneys (nephritis), or nervous system (encephalitis, Guillain-Barré syndrome), plus rare cases like heart inflammation (myocarditis) or infusion reactions.[1][2]
Patients often experience these within weeks to months of starting treatment, though some emerge later. Symptoms vary: shortness of breath or cough for pneumonitis, diarrhea or abdominal pain for colitis, jaundice or fatigue for hepatitis, or headaches and vision changes for hypophysitis.
Immediate Steps for Suspected Serious Side Effects
Stop Keytruda immediately and contact your oncologist or seek emergency care if symptoms are severe (e.g., grade 3-4 per CTCAE criteria: life-threatening or requiring hospitalization). Do not wait for the next infusion—early intervention prevents organ damage.[1][3]
- Monitor closely: Regular blood tests, imaging (CT scans for lungs), and stool tests track inflammation markers like CRP, liver enzymes, or fecal calprotectin.
- Report promptly: Use patient portals or hotlines provided by treatment centers. FDA requires monitoring for irAEs during and up to 12 months post-treatment.[2]
Primary Management: Corticosteroids as First-Line
High-dose corticosteroids are the cornerstone for most serious irAEs, given IV or orally to suppress immune overactivity.[1][3]
| Organ Affected | Typical Steroid Regimen | Duration |
|---------------|-------------------------|----------|
| Colitis/pneumonitis | Methylprednisolone 1-2 mg/kg/day IV | Taper over 4-6 weeks after improvement |
| Hepatitis | Prednisone 1-2 mg/kg/day oral | Taper based on liver function normalization |
| Endocrinopathies (e.g., hypophysitis) | High-dose then hormone replacement | Lifelong for permanent damage |
| Myocarditis | High-dose IV steroids ± immunosuppressants | Urgent, often ICU monitoring |
Improvement usually occurs within days; if no response in 48-72 hours, escalate to second-line therapies.
When Steroids Fail: Second- and Third-Line Options
About 20-30% of severe cases need additional immunosuppressants.[3]
- Infliximab (Remicade): Anti-TNF agent for refractory colitis or pneumonitis; single infusion often suffices, but avoid in infections.[1]
- Vedolizumab: Gut-specific for colitis, preserving systemic immunity.
- Mycophenolate or azathioprine: For hepatitis or multi-organ irAEs.
- Other: Tocilizumab (IL-6 inhibitor) for cytokine storms; plasma exchange or IVIG for neurological issues like Guillain-Barré.
Permanently discontinue Keytruda for life-threatening irAEs (e.g., myocarditis, encephalitis); rechallenge possible in milder cases after resolution.[2]
Supportive Care and Prevention Strategies
- Hydration and nutrition: IV fluids for colitis; nutritional support to prevent weight loss.
- Symptom-specific: Antibiotics for secondary infections; hormone replacement (e.g., levothyroxine for hypothyroidism) for endocrine failures.
- Preventive measures: Prophylactic steroids for high-risk patients (prior irAEs); baseline organ function tests; patient education on symptom diaries.[3]
- Multidisciplinary teams: Involve endocrinologists, pulmonologists, or gastroenterologists alongside oncologists.
Long-Term Outlook and Patient Concerns
Most irAEs resolve with treatment (80-90% success rate), but 10-20% cause permanent damage like diabetes or hypothyroidism requiring lifelong management.[3] Risks rise with combination therapies (e.g., Keytruda + chemo). Patients often ask about fertility impacts (minimal direct effect, but steroids can affect it) or resuming treatment—only after full recovery and specialist approval.
Follow NCCN or ASCO guidelines for standardized protocols. Always tailor to individual cases under medical supervision.
Sources
[1]: Keytruda Prescribing Information (Merck)
[2]: FDA Label for Pembrolizumab
[3]: NCCN Guidelines: Management of Immunotherapy-Related Toxicities